{"entity":{"id":"paper-eln-apl-sanz-blood-2019","kind":"paper","name":"European LeukemiaNet recommendations for the management of acute promyelocytic leukaemia (2019 update)","aka":[],"tldr":"The expert panel guidance on acute promyelocytic leukaemia covers the emergency first hours, the choice between arsenic-based and chemotherapy-based regimens by risk, differentiation syndrome, and molecular monitoring.","summary":"Updated recommendations from a European LeukemiaNet expert panel on diagnosis, supportive care for coagulopathy, risk-adapted treatment with all-trans retinoic acid and arsenic trioxide or chemotherapy, management of differentiation syndrome, molecular monitoring and treatment of relapse.","asOf":"2026-09-17","links":[{"label":"Blood 2019","url":"https://doi.org/10.1182/blood-2019-01-894980"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/30803991/"}],"tags":[],"related":[],"cancers":["apl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood"],"dependsOn":[],"notes":[],"journal":"Blood","year":2019,"doi":"10.1182/blood-2019-01-894980","pmid":"30803991","authors":"Sanz MA, Sanz MA, Fenaux P, et al.","paperType":"guideline","findings":[],"whatItMeans":"Starting retinoic acid on morphological suspicion, aggressive blood product support and arsenic-based induction for non-high-risk disease all follow from this document.","caveats":["Oral arsenic and gemtuzumab-based regimens for high-risk disease have evolved since publication."],"changedPractice":true},"route":"/key-papers/paper-eln-apl-sanz-blood-2019/","neighbours":{"cancer":[{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/"}],"journal":[{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/"}]}}